HERTFORDSHIRE, England and PITTSBURGH, June 30, 2020 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company's extraordinary general meeting of shareholders. Approximately 99.6% of votes cast were voted in favor of the combination.
Mylan Executive Chairman and Future Viatris Executive Chairman Robert J. Coury said: "The near unanimous support we have received from our shareholders with 99.6% of shares voted in favor of this transaction truly validates the extensive analysis and time invested by the board's strategic review committee, and the full board, in identifying the right opportunity to unlock the true value of our one-of-a-kind platform as well as accelerate Mylan's next exciting phase of growth. The overwhelming endorsement we received from shareholders only further bolsters our confidence in the value that we believe the new company will deliver, and we are very excited to soon create Viatris, expected in the fourth quarter of this year."
Coury continued: "Viatris will be launched with a robust new business model, focused on total shareholder return. With an enhanced balance sheet and financial flexibility, we will be able to implement a more shareholder-friendly capital allocation policy starting with a dividend of at least 25% of our free cash flow following Viatris' first full quarter after close. We also look forward to introducing Viatris' new, unique GLOBAL HEALTHCARE GATEWAY, which will offer partners ready access to more markets and patients worldwide through the company's unmatched global infrastructure and expertise, making Viatris a true Partner of Choice."
Coury closed: "With this significant milestone behind us and our permanent financing now in place, we look forward to obtaining the remaining regulatory approvals and completing the transaction."
Mylan will file the vote results in a Form 8-K with the U.S. Securities and Exchange Commission.
The transaction is subject to customary closing conditions, including receipt of the remaining required regulatory approvals.
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our ~35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.
Mylan Executive Chairman and Future Viatris Executive Chairman Robert J. Coury said: "The near unanimous support we have received from our shareholders with 99.6% of shares voted in favor of this transaction truly validates the extensive analysis and time invested by the board's strategic review committee, and the full board, in identifying the right opportunity to unlock the true value of our one-of-a-kind platform as well as accelerate Mylan's next exciting phase of growth. The overwhelming endorsement we received from shareholders only further bolsters our confidence in the value that we believe the new company will deliver, and we are very excited to soon create Viatris, expected in the fourth quarter of this year."
Coury continued: "Viatris will be launched with a robust new business model, focused on total shareholder return. With an enhanced balance sheet and financial flexibility, we will be able to implement a more shareholder-friendly capital allocation policy starting with a dividend of at least 25% of our free cash flow following Viatris' first full quarter after close. We also look forward to introducing Viatris' new, unique GLOBAL HEALTHCARE GATEWAY, which will offer partners ready access to more markets and patients worldwide through the company's unmatched global infrastructure and expertise, making Viatris a true Partner of Choice."
Coury closed: "With this significant milestone behind us and our permanent financing now in place, we look forward to obtaining the remaining regulatory approvals and completing the transaction."
Mylan will file the vote results in a Form 8-K with the U.S. Securities and Exchange Commission.
The transaction is subject to customary closing conditions, including receipt of the remaining required regulatory approvals.
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our ~35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.
